pyrroles has been researched along with Nausea in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Coric, V; Croop, R; Harris, L; Johnston, KM; L'Italien, G; Popoff, E; Powell, L | 1 |
| Ailani, J; Dodick, DW; Finnegan, M; Lipton, RB; Lu, K; Szegedi, A; Trugman, JM | 2 |
| Ailani, J; Finnegan, M; Goadsby, PJ; Guo, H; Lipton, RB; Miceli, R; Severt, L; Trugman, JM | 1 |
| Broder, MS; Chang, E; Neary, MP; Reddy, SR | 1 |
| Blackwood, EM; Cousin, S; DuPree, K; Epler, J; Hamilton, E; Hollebecque, A; Infante, JR; Italiano, A; Lauchle, JO; LoRusso, PM; Lu, X; Mahrus, S; Moein, A; Moore, KN; Murray, ER; Peale, FV; Postel-Vinay, S; Schutzman, JL; Shapiro, GI; Soria, JC; Tagen, M; Tolaney, S; Toulmonde, M | 1 |
| Bekaii-Saab, T; Clinton, SK; Grever, MR; Kraut, EH; Martin, LK; Monk, P; Serna, D | 1 |
| Charles, LP; DeAnnuntis, L; Escudier, B; Gore, ME; Hariharan, S; Motzer, RJ; Porta, C; Rini, BI; Yang, L | 1 |
| Barett, C; Bikas, A; Burman, KD; Clark, BG; Desale, S; Gandhi, R; Jelinek, JS; Kundra, P; Mete, M; O'Keefe, K; Wartofsky, L; Wexler, JA; Wray, L | 1 |
| Blumenstengel, K; Busies, S; Hutzschenreuter, U; Marschner, N; Müller, L; Münch, A | 1 |
| Choi, HY; Chung, J; Jeon, SH; Kim, SH; Kim, WJ; Kim, YJ; Kwon, TG; Lee, HL; Lee, HM; Seo, SI | 1 |
| Beniak, J; Kakalejcik, M; Reckova, M | 1 |
| Bloom, BJ; Breedveld, FC; Burgos-Vargas, R; Coombs, JH; Fletcher, MP; Gruben, D; Kremer, JM; Krishnaswami, S; Wilkinson, B; Zerbini, CA; Zwillich, SH | 1 |
| Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM | 1 |
| Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF | 1 |
| Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S | 1 |
| Brickman, MJ; Citrin, DL; Dees, EC; Healey, P; Kern, KA; Li, S; Myers, SD; Paolini, J; Wang, Z; Yardley, DA | 1 |
| Cropp, G; Gosalia, R; Hannah, A; Sheldon, M; Stopeck, A; Vahedian, M | 1 |
| Ballantyne, CM; Blazing, MA; Davidson, MH; DeLucca, P; Hunninghake, DB; Hustad, CM; Palmisano, J; Ramsey, KE; Yuan, Z | 1 |
| Atkins, JN; Belani, CP; Brahmer, JR; Chao, RC; Gillenwater, HH; Govindan, R; Novello, S; Pallares, C; Rosell, R; Sanchez, JM; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L | 1 |
| Ito, H; Iwaoka, K; Kiso, T; Miyata, K; Naitoh, Y; Yamaguchi, T; Yuki, H | 1 |
| Frigerio, G | 1 |
1 review(s) available for pyrroles and Nausea
| Article | Year |
|---|---|
Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.
Topics: Adult; Bayes Theorem; Benzamides; Dizziness; Double-Blind Method; Humans; Migraine Disorders; Nausea; Piperidines; Pyridines; Pyrroles; Serotonin Receptor Agonists; Treatment Outcome | 2022 |
14 trial(s) available for pyrroles and Nausea
| Article | Year |
|---|---|
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Topics: Adult; Aged; Analgesics; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Pain; Pain Management; Pyridines; Pyrroles; Young Adult | 2019 |
Ubrogepant for the Treatment of Migraine.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperacusis; Kaplan-Meier Estimate; Male; Migraine Disorders; Nausea; Pain Management; Photophobia; Pyridines; Pyrroles | 2019 |
Atogepant for the Preventive Treatment of Migraine.
Topics: Adolescent; Adult; Aged; Calcitonin Gene-Related Peptide Receptor Antagonists; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Migraine Disorders; Nausea; Piperidines; Pyridines; Pyrroles; Spiro Compounds; Young Adult | 2021 |
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thrombocytopenia; Treatment Outcome | 2018 |
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrroles; Thrombocytopenia; Treatment Outcome | 2013 |
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Iodine Radioisotopes; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Pyrroles; Radiotherapy; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Prospective Studies; Pyrroles; Quality of Life; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
Topics: Arthritis, Rheumatoid; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; International Cooperation; Janus Kinases; Male; Middle Aged; Nausea; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2009 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vomiting; Young Adult | 2010 |
Phase II open-label study of sunitinib in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Middle Aged; Nausea; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2012 |
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Endothelial Growth Factors; Fatigue; Female; Fibroblast Growth Factor 2; Headache; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Middle Aged; Molecular Structure; Nausea; Neoplasms; Pyrroles; Salvage Therapy; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vomiting | 2002 |
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
Topics: Adult; Aged; Alkaline Phosphatase; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Diarrhea; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Nausea; Pyrroles; Simvastatin | 2003 |
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pain; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Stomatitis; Sunitinib; Treatment Outcome | 2008 |
[Viminol in the treatment of pain. Double-blind, controlled, multicentric trial].
Topics: Aminopyrine; Analgesics; Aspirin; Benzoates; Benzyl Compounds; Dextropropoxyphene; Drug Evaluation; Drug Tolerance; Ethanolamines; Female; Humans; Male; Morphine; Nausea; Pain; Pentazocine; Phenylbutazone; Pyrroles; Sleep Wake Disorders; Vertigo | 1974 |
7 other study(ies) available for pyrroles and Nausea
| Article | Year |
|---|---|
Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cost of Illness; Everolimus; Humans; Indoles; Middle Aged; Molecular Targeted Therapy; Nausea; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Vomiting; Young Adult | 2017 |
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
Topics: Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Dysgeusia; Dyspepsia; Fatigue; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Mucositis; Nausea; Pyrroles; Stomatitis; Sunitinib; Time Factors | 2016 |
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Documentation; Fatigue; Female; Germany; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Registries; Sirolimus; Sorafenib; Stomatitis; Sunitinib | 2017 |
Treatment of hemodialyzed patient with sunitinib.
Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Coronary Artery Bypass; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Indoles; Male; Middle Aged; Nausea; Nephrectomy; Pyrroles; Remission Induction; Renal Dialysis; Sunitinib; Thrombocytopenia; Treatment Outcome; Vomiting | 2009 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Bisoprolol; Bone Neoplasms; Capecitabine; Colic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Heptanoic Acids; Humans; Hypercholesterolemia; Ileus; Leucovorin; Lymphatic Metastasis; Middle Aged; Nausea; Pyrroles; Ventricular Premature Complexes; Vomiting | 2011 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia | 2011 |
Investigation of the effects of YM-31636, a novel 5-HT3 receptor agonist, on defecation in normal and constipated ferrets.
Topics: Animals; Citrates; Constipation; Defecation; Dose-Response Relationship, Drug; Feces; Ferrets; Male; Nausea; Organometallic Compounds; Picolines; Pyrroles; Serotonin Receptor Agonists; Thiazoles; Time Factors; Vomiting; Water | 2001 |